论文部分内容阅读
目的分析两种红细胞制品治疗阵发性睡眠性血红蛋白尿症(PNH)的治疗效果,为临床治疗提供依据。方法将2009-2014年入院治疗的50名PNH患者作为研究对象,将其按照输注红细胞制品分为去白悬浮红细胞组和洗涤红细胞组,观察两组患者输血疗效及输血不良反应。结果去白悬浮红细胞组和洗涤红细胞组的血液成分输注后红细胞(RBC)增值、血红蛋白(Hb)增值和红细胞比容(Hct)增值比较,差异无统计学意义(t=0.737,P=0.462;t=0.795,P=0.428;t=-0.006,P=0.995)。两组输血不良反应发生率较低(χ~2=0.318,P=0.573),均未出现明确的溶血性输血不良反应。结论去白悬浮红细胞治疗阵发性睡眠性血红蛋白尿症贫血疗效确切,输血不良反应并未增加,值得临床推广。
Objective To analyze the curative effect of two kinds of erythrocyte products in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and provide the basis for clinical treatment. Methods Fifty PNH patients hospitalized from 2009 to 2014 as study subjects were divided into three groups according to the transfusion of erythrocyte products: white blood transfusion group and red blood cell group. The transfusion efficacy and adverse transfusion reactions were observed in two groups. Results There was no significant difference in RBC value, Hb value and Hct value after transfusion of white blood cell suspension and washed red blood cell group (t = 0.737, P = 0.462 ; t = 0.795, P = 0.428; t = -0.006, P = 0.995). Adverse reactions of blood transfusion in both groups were lower (χ ~ 2 = 0.318, P = 0.573), and no definite haemolytic transfusion adverse reactions were found. Conclusion White blood cell suspension erythrocyte treatment of paroxysmal nocturnal hemoglobinuria anemia curative effect is accurate, adverse reactions did not increase blood transfusion, is worth clinical promotion.